CY1108050T1 - Η χρηση της μεκαμυλαμινης για τη θεραπεια των ανταποκρινομενων στη νικοτινη νευροψυχιατρικων διαταραχων - Google Patents

Η χρηση της μεκαμυλαμινης για τη θεραπεια των ανταποκρινομενων στη νικοτινη νευροψυχιατρικων διαταραχων

Info

Publication number
CY1108050T1
CY1108050T1 CY20081100342T CY081100342T CY1108050T1 CY 1108050 T1 CY1108050 T1 CY 1108050T1 CY 20081100342 T CY20081100342 T CY 20081100342T CY 081100342 T CY081100342 T CY 081100342T CY 1108050 T1 CY1108050 T1 CY 1108050T1
Authority
CY
Cyprus
Prior art keywords
mekamylamine
nicotines
neurotherapeutic
disorders
treatment
Prior art date
Application number
CY20081100342T
Other languages
English (en)
Inventor
Paul Ronald Sanberg
Ronald Douglas Shytle
Archie Aaron Silver
Original Assignee
University Of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of South Florida filed Critical University Of South Florida
Publication of CY1108050T1 publication Critical patent/CY1108050T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ανταποκρινόμενες στη νικοτίνη νευροψυχιατρικές διαταραχές μπορούν να υποβληθούν σε θεραπεία χορηγώντας ένα ανταγωνιστή νικοτίνης, συγκεκριμένα τη μεκαμυλαμίνη. Η θεραπεία συνδυασμού της μεκαμυλαμίνης με ένα νευροληπτικό φάρμακο αποκαλύπτεται επίσης. Οι νευροψυχιατρικές διαταραχές περιλαμβάνουν το σύνδρομο Tourette, τη σχιζοφρένια, τη κατάθλιψη, τη διπολική διαταραχή, τους τρόμους, τη διαταραχή διάσπασης της προσοχής και υπερκινητικότητας, την ιδεοψυχαναγκαστική διαταραχή, την ημιδυστονία, τα ξεσπάσματα οργής, και την όψιμη δυσκινησία.
CY20081100342T 1997-08-11 2008-03-07 Η χρηση της μεκαμυλαμινης για τη θεραπεια των ανταποκρινομενων στη νικοτινη νευροψυχιατρικων διαταραχων CY1108050T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5523497P 1997-08-11 1997-08-11
US93536497A 1997-09-22 1997-09-22
PCT/US1997/020689 WO1999007356A1 (en) 1997-08-11 1997-11-07 Nicotine antagonists for neuropsychiatric disorders
EP98939328A EP1011678B1 (en) 1997-08-11 1998-08-11 Use of mecamylamine for the treatment of nicotine-responsive neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
CY1108050T1 true CY1108050T1 (el) 2013-09-04

Family

ID=26734003

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100342T CY1108050T1 (el) 1997-08-11 2008-03-07 Η χρηση της μεκαμυλαμινης για τη θεραπεια των ανταποκρινομενων στη νικοτινη νευροψυχιατρικων διαταραχων

Country Status (8)

Country Link
EP (1) EP1011678B1 (el)
AR (1) AR021160A1 (el)
AT (1) ATE381324T1 (el)
CY (1) CY1108050T1 (el)
DE (1) DE69838875T2 (el)
PT (1) PT1011678E (el)
TW (1) TWI233354B (el)
WO (1) WO1999007356A1 (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60307049T2 (de) * 2003-04-25 2007-02-08 Neuro3D Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS
US20080058345A1 (en) * 2004-01-06 2008-03-06 Tony George Combination Therapy with Mecamylamine for the Treatment of Mood Disorders
GB202203728D0 (en) * 2022-03-17 2022-05-04 Univ Oxford Innovation Ltd Treatments and methods for increasing dopamine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4837218A (en) * 1987-10-23 1989-06-06 Washington University Alkylated bicycloalkaneamines for treatment of neurotoxic injury
CA2080536A1 (en) * 1991-10-17 1993-04-18 John S. Ward Nicotinic activity of a series of arecolones and isoarecolones
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders

Also Published As

Publication number Publication date
EP1011678A1 (en) 2000-06-28
DE69838875D1 (de) 2008-01-31
WO1999007356A1 (en) 1999-02-18
ATE381324T1 (de) 2008-01-15
PT1011678E (pt) 2008-02-07
DE69838875T2 (de) 2008-12-04
EP1011678B1 (en) 2007-12-19
EP1011678A4 (en) 2004-01-14
AR021160A1 (es) 2002-07-03
TWI233354B (en) 2005-06-01

Similar Documents

Publication Publication Date Title
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
FI960727A0 (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
ATE398618T1 (de) Pharmazeutische zusammensetzungen zur behandlung von zns und anderen krankheiten
DE69527053D1 (de) Naphtylamides als zentralnervensystemmittel
PL307741A1 (en) Derivatives of arylindene and heteroarylindene oxindole used as tyrosine kinase inhibitors
YU62294A (sh) Novi (r)-5-karbamoil-8-fluoro-3-n-n-disupstituisani-3,4--dihidro-2h-1-benzopirani
ATE348829T1 (de) Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen
BG102999A (en) New 2,3-diasubstituted-4-(3h)-quinazolinons
ES2164889T3 (es) Semicarbazonas con actividad sobre el snc y preparados farmaceuticos a base de las mismas.
FI913142A (fi) Migraenfoerhindrande alkoxipyrimidinderivat.
NO20041166L (no) Anvendelse av optisk rent (+) norcisaprid sammen med et annet terapeutisk middel for fremstilling av et medikament
DE60016460D1 (de) Verwendungen und zusammenstellungen von nitratestern als sedativa
DK0615751T3 (da) Anvendelse af tachykininantagonister til behandling af emesis
ES2133714T3 (es) Compuestos heterociclicos para el tratamiento de trastornos del snc y cardiovasculares.
DK0520200T3 (da) Imadazol-forbindelser, deres fremstilling og anvendelse
CY1108050T1 (el) Η χρηση της μεκαμυλαμινης για τη θεραπεια των ανταποκρινομενων στη νικοτινη νευροψυχιατρικων διαταραχων
ATE225177T1 (de) Verwendung von (+)mefloquine zur behandlung von malaria
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
DK0871446T3 (da) Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve
ATE173263T1 (de) Imidazolochinoxalinonderivate als eaa antagonisten
GB9913458D0 (en) The therapeutic use of d-threo-methylphenidate
CA2300148A1 (en) Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
KR950700286A (ko) 2,3,4,5-테트라하이드로-1H-3-벤즈아제핀 및 약제학적으로 허용가능한 이의 산 부가염(2,3,4,5-Tetrahydro-1H-3-benzazepines and pharmaceutically acceptable acid addition salts thereof)
PE26198A1 (es) Compuestos farmaceuticos